Miami, FL – Promptly Technology, Inc., a leader in streamlining patient engagement, secured strategic minority investments led by Telegraph Hill Partners. This growth capital will

PHILADELPHIA, April 1, 2024 /PRNewswire/ — ObservSMART, a leading proximity-based technology system for ensuring patient safety in healthcare settings, proudly announces the accomplishment of reaching 1

EditCo is focused on the development and manufacture of highly optimized CRISPR guide RNA designs and edited cells for the global cell biology and gene

Company Announces Appointment of Daniel Flynn, Ph.D. and Brian Cali, Ph.D. to Strengthen Capabilities in Support of Company’s Peptide Drug Programs MADISON, Wis.–(BUSINESS WIRE)–Nimble Therapeutics

Investment strengthens Argonaut’s leadership position in sterile fill / finish and expands the Company’s aseptic drug product manufacturing capabilities in pre-filled syringes and cartridges Carlsbad,

Pleasanton, California – February 7, 2024 – n6 Tec Inc., a next generation sequencing and molecular biology platform company, announced the completion of a growth

iconPCR enables optimal high-throughput PCR for next generation sequencing and molecular biology applications PLEASANTON, CA – February 6, 2024— n6 Tec has launched the world’s

Panome Bio adds deep, unbiased proteomics to their proprietary metabolomics platform to deliver innovative multi-omics services REDWOOD CITY, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) —

Positions the Company as a new leader in providing solutions that bridge the gap between cellular electrophysiology and advanced analysis techniques DURHAM, NORTH CAROLINA, UNITED

ST. LOUIS, March 15, 2023 /PRNewswire/ — Panome Bio, a metabolomics and proteomics services company that provides biopharma innovators unparalleled access into the biomolecules closest

VENLO, The Netherlands & SAN DIEGO–(BUSINESS WIRE)– QIAGEN (NYSE:QGEN; Frankfurt Prime Standard: QIA) today announced it has completed the acquisition of Verogen, a leader in the

Madison, WI USA, January 5, 2023–/BusinessWire/ — Nimble Therapeutics, a biotechnology company leveraging its next-generation peptide discovery platform to identify medicines for challenging-to-drug targets, today